Navigation Links
First targeted and programmable nanomedicine to show clinical antitumor effects published
Date:4/4/2012

stitute, Weill Cornell Medical College, the Translational Genomics Research Institute (TGen), Karmanos Cancer Institute and Wayne State University.

"We are very excited about the results of our preclinical development, and successful clinical translation of BIND-014. The initial Phase 1 clinical efficacy and safety in advanced and metastatic cancers demonstrate promise for BIND-014 and provide strong validation for our Accurin platform to develop targeted therapeutics that accumulate at the site of disease to maximize therapeutic effect," said Jeff Hrkach, Ph.D., Senior Vice President, Technology Research and Development of BIND Biosciences. "BIND-014 represents the lead Accurin product to enter the clinic from our pipeline and is an ideal example of the power of our proprietary platform to develop targeted therapeutics."

About BIND-014

BIND-014 is a programmable nanomedicine that combines a targeting ligand and a therapeutic nanoparticle. BIND-014 contains docetaxel, a proven cancer drug which is approved in major cancer indications including breast, prostate and lung, encapsulated in FDA-approved biocompatible and biodegradable polymers. BIND-014 is targeted to prostate specific membrane antigen (PSMA), a cell surface antigen abundantly expressed on the surface of cancer cells and on new blood vessels that feed a wide array of solid tumors. In preclinical cancer models, BIND-014 was shown to deliver up to ten-fold more docetaxel to tumors than an equivalent dose of conventional docetaxel. The increased accumulation of docetaxel at the site of disease translated to marked improvements in antitumor activity and tolerability. BIND-014 is currently in Phase 1 human clinical testing in patients with advanced or metastatic solid tumor cancers (NCT01300533). The early development of BIND-014 was funded in part by the National Cancer Institute and the U.S. National Institutes of Standards and Technology (NIST) under its Advanced Technology Program
'/>"/>

Contact: Kathryn Morris
kathryn@theyatesnetwork.com
914-204-6412
The Yates Network
Source:Eurekalert

Page: 1 2 3 4

Related biology technology :

1. MiMedx Exceeds Revenue Goal for First Quarter of 2012
2. FirstMark Exhibiting at the American College of Cardiology 61st Annual Scientific Sessions & Expo
3. Expanded Findings for FirstMarks Completed Clinical Study for Predicting Near-Term (2-3 Years) MI
4. Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer
5. Researchers capture first-ever images of atoms moving in a molecule
6. Be One of the First to Experience Medtrack One View at the AUTM 2012 Annual Meeting
7. First Statewide Biotech Meeting Focuses on Patient Access, Innovation
8. Inaugural Meeting of the FirstMark Scientific Board of Advisors
9. AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001
10. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
11. Penn researchers build first physical metatronic circuit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014   Sequenom, Inc. ... company that provides innovative genetic analysis solutions, and ... esoteric laboratory services in the United States ... prenatal testing patents and applications. "We have ... and patient care, and we welcome the opportunity to ...
(Date:7/29/2014)... separated from its properties? On July 29, the prestigious ... the first Cheshire Cat experiment, separating a neutron from ... CA, and Vienna University of Technology. , Chesire Cat"Well! ... Alice in Wonderland, "but a grin without a cat! ... my life!" Alice,s surprise stems from her experience that ...
(Date:7/29/2014)... created a new way of manufacturing microstructured surfaces ... by self-assembly of carbon nanotubes, could exhibit a ... stiffness and strength, or the ability to repel ... demonstrated that mechanical forces can be used to ... that we can independently control the mechanical ...
(Date:7/29/2014)... 2014  Pomerantz LLP is investigating claims on behalf ... "Company") (NASDAQ: IPXL).  Such investors are advised to contact ... or 888-476-6529, ext. 237. The investigation concerns ... have violated Sections 10(b) and 20(a) of the Securities ... 29, 2014, Impax Laboratories, Inc. (the "Company") issued a ...
Breaking Biology Technology:Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4The quantum Cheshire cat: Scientists separate a particle from its properties 2The quantum Cheshire cat: Scientists separate a particle from its properties 3The quantum Cheshire cat: Scientists separate a particle from its properties 4A new way to make microstructured surfaces 2SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2
... 30 VEGA PROMOTIONAL SYSTEMS, INC. (Pink Sheets: VGPR) today ... Power Company, Inc. to assist the Company in building a ... Vega recently announced its intention to build a biomass plant ... materials in the State,s Bioenergy Corridor. Georgia ranks third ...
... Novavax, Inc. (Nasdaq: NVAX ) announced today ... (VLP) vaccine technology to ROVI Pharmaceuticals (Madrid: ROVI) of ... create a comprehensive influenza vaccine solution for the Spanish ... led by the Spanish Ministry of Health and other ...
... Bion Environmental Technologies, Inc. (OTC Bulletin Board: BNET) ... Patent application 11/592,513 entitled "Low Oxygen Biologically Mediated Nutrient ... on November 6, 2006; upon publication and issuance, the ... force until November 5, 2024. This new patent strengthens ...
Cached Biology Technology:Vega Picks Tennessee Firm to Assist with Construction of Biomass Plant in Georgia 2Spanish Government Selects Novavax's VLP Technology for Comprehensive Flu Vaccine Solution in Spain 2Spanish Government Selects Novavax's VLP Technology for Comprehensive Flu Vaccine Solution in Spain 3Spanish Government Selects Novavax's VLP Technology for Comprehensive Flu Vaccine Solution in Spain 4Spanish Government Selects Novavax's VLP Technology for Comprehensive Flu Vaccine Solution in Spain 5Bion Announces Approval of New U.S. Patent that Broadens Protection for the Company's Livestock Waste Environmental Treatment Processes 2
(Date:7/29/2014)... wrong food at a restaurant, don,t blame yourself; blame the ... with what you want and more to do with a ... the selections of over 300 diners, the Cornell study published ... showed that when it comes to what you order ... the menu and how you imagine it will taste. , ...
(Date:7/29/2014)... debilitating effects of a stroke is an immensely ... as well as effective therapy. Advancing such knowledge ... the primary focus of research by Sergei Adamovich, ... the NJIT faculty more than a decade ago. ... substantial funding from sources such as the National ...
(Date:7/29/2014)... developed an easier method to create DNAprotein conjugates. ... in diagnosing diseases. , DNA linked to proteins ... that can be used in diagnostic techniques, nanotechnology ... proteins with DNA can be used for ... of biological material. The method also provides easier ...
Breaking Biology News(10 mins):Menu secrets that can make you slim by design 2Continuing the quest for better stroke therapies 2Continuing the quest for better stroke therapies 3New method provides researchers with efficient tool for tagging proteins 2
... February 20, 2012A team of researchers has found a ... will continue to be available, despite the potential attack ... Disease and poses a significant threat to the California ... Alamos National Laboratory (LANL), University of California at Davis ...
... PA, February 21, 2012 Using a noninvasive test on ... new algorithm for analysis, scientists can detect, with a high ... chromosomal abnormalities that cause Down syndrome and a genetic disorder ... scalable than other recently developed genetic screening tests and has ...
... has awarded The University of Texas at Austin and ... Dynamics Collaboratory (DDC), a network of researchers working to ... reliably predict the physical and ecological evolution of river ... the project, including Paola Passalacqua, assistant professor in Civil, ...
Cached Biology News:More grapes, less wrath: Hybrid antimicrobial protein protects grapevines from pathogen 2Noninvasive method accurately and efficiently detects risk of Down syndrome 2Noninvasive method accurately and efficiently detects risk of Down syndrome 3Engineering, geoscience faculty help lead $3 million NSF Delta research collaboration 2
... The HEEBO (Human Exonic Evidence Based ... Evidence Based Oligonucleotide ) Genome Set contain ... largely derived from constitutively expressed exons, allowing ... collaboration with leading researchers at Stanford University ...
odz, odd Oz/ten-m homolog 1 [Source:RefSeq_peptide;Acc:NP_055068] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Rabbit polyclonal to FANCE ( Abpromise for all tested applications). entrezGeneID: 2178 SwissProtID: Q9HB96...
Rabbit polyclonal to NIRF ( Abpromise for all tested applications). Antigen: Synthetic peptide derived from residues 186-235 of human NIRF. Entrez Gene ID: 115426 Swiss Protein ID: Q96PU...
Biology Products: